Background: Roifman syndrome is a rare inherited disorder characterized by spondyloepiphyseal dysplasia, growth retardation, cognitive delay, hypogammaglobulinemia, and, in some patients, thrombocytopenia. Compound heterozygous variants in the small nuclear RNA gene RNU4ATAC, which is necessary for U12-type intron splicing, were identified recently as driving Roifman syndrome. Objective: We studied 3 patients from 2 unrelated kindreds harboring compound heterozygous or homozygous stem II variants in RNU4ATAC to gain insight into the mechanisms behind this disorder. Methods: We systematically profiled the immunologic and hematologic compartments of the 3 patients with Roifman syndrome and performed RNA sequencing to unravel important splicing defects in both cell lineages. Results: The patients exhibited a dramatic reduction in B-cell numbers, with differentiation halted at the transitional B-cell stage. Despite abundant B-cell activating factor availability, development past this B-cell activating factor-dependent stage was crippled, with disturbed minor splicing of the critical mitogen-activated protein kinase 1 signaling component. In the hematologic compartment patients with Roifman syndrome demonstrated defects in megakaryocyte differentiation, with inadequate generation of proplatelets. Platelets from patients with Roifman syndrome were rounder, with increased tubulin and actin levels, and contained increased a-granule and dense granule markers. Significant minor intron retention in 354 megakaryocyte genes was observed, including DIAPH1 and HPS1, genes known to regulate platelet and dense granule formation, respectively. Roifman syndrome (OMIM#616651) is a rare disorder characterized by growth retardation, cognitive delay, retinal dystrophy, spondyloepiphyseal dysplasia, and immunodeficiency. [1] [2] [3] [4] Compound heterozygous variants in the small nuclear RNA (snRNA) noncoding gene RNU4ATAC have been found recently to cause Roifman syndrome. 5 This gene encodes U4atac, an snRNA that is indispensable for minor splicing and is responsible for removing U12-type introns. [6] [7] [8] The presence of U12-type introns is associated with genes involved in RNA processing and DNA repair, 9 but other processes can also be affected.
To date, only 10 patients with Roifman syndrome from 7 pedigrees have been reported with causal variants in the RNU4ATAC gene. 5, 10, 11 Microcephalic osteodysplastic primordial dwarfism type 1 (MOPD1; OMIM#210710) has also been associated with recessive variants in conserved regions of RNU4ATAC. 12, 13 Although described as clinically distinct conditions, the identification of causal variants in the same gene suggest that differential downstream effects drive the clinical differences between Roifman syndrome and MOPD1. Patients with MOPD1 in general seem to present with a more severe developmental phenotype than patients with Roifman syndrome. Their main features consist of skeletal dysplasia, microcephaly 14 Therefore it was hypothesized that mutations in MOPD1-associated regions of RNU4ATAC are of greater importance for minor intron splicing 5 or, conversely, are required for the minor intron splicing of genes with more critical functions in development. Patients with reported Roifman syndrome carry only 1 RNU4ATAC variant in either the critical region of the 59 stem loop or (adjacent to) the Sm protein binding site, both of which are considered elements of crucial importance for splicing. The second variant is located in stem II, which has not been associated with MOPD1 (Fig 1, A) . 5 Only recently, it was advocated that homozygous stem II variants are even sufficient to cause Roifman syndrome, pointing at a large effect of this region on the resulting patient phenotype. 10 The difference between alleles can also be related to differential downstream targets rather than to variant severity. Indeed, the different Roifman syndrome-and MOPD1-implicated regions interact with different proteins because the 59 stem loop critical region binds mainly to NHP2L1 and PRPF31, and the stem II region interacts with PRPF4/PRPF3/PPIH. 15 This implies that the highly variable spectrum of both disorders depends on the subset of genes affected (and their degree of minor intron retention).
The presence of clinically overt immunodeficiency in patients with Roifman syndrome indicates an underlying dysfunction in the immunologic compartment. Clinical workup has revealed previously low numbers of circulating B cells and hypogammaglobulinemia. 1, 2, 5, 10, 11 At the hematologic level, low platelet counts have been reported. 1, 16 Potential explanations for these observations are aberrant X-ray repair crosscomplementing protein 5 (XRCC5) splicing leading to defective B-cell receptor (BCR) recombination 5 and immune thrombocytopenia (ITP) as a cause of low blood platelet counts. 16 Here we have investigated the immunologic and hematologic systems of 3 patients with Roifman syndrome from 2 unrelated kindreds bearing RNU4ATAC variants. Through coupled cellular biology and transcriptional analysis, we identified key gene-splicing defects capable of explaining the immune and blood phenotypes found in patients with Roifman syndrome.
METHODS

Patient recruitment and genotyping
Whole-genome sequencing was performed for all 3 patients with Roifman syndrome as part of the BRIDGE-BPD project. Details for the genetic analysis have been described previously. [17] [18] [19] Genes were ranked by using Bayesian Evaluation of Variant Involvement in Mendelian Disorders (BeviMed), which models the association between configurations of allele counts at rare variants in a locus and case-control labels. 19 Sanger sequencing of the RNU4ATAC gene was performed according to amplification with the primers 59CTGTGGAGG CTGGAGGTAAGC39 and 59TTACTTGCGACACTAAAACCA39.
Flow cytometry
Blood samples were collected in lithium-heparin tubes for separation of plasma and PBMCs with lymphocyte separation medium (MP Biomedicals, Santa Ana, Calif). PBMCs were frozen in 10% dimethyl sulfoxide (Sigma, St Louis, Mo) and stored at 2808C for a maximum of 10 weeks. Thawed PBMCs were stained with antibodies (see the Methods section in this article's Online Repository at www.jacionline.org). Forkhead box p3 staining was performed after treatment with Fixation & Permeabilization Buffer (eBioscience, San Diego, Calif). Data were acquired on a BD FACSCanto II and analyzed with FlowJo software (TreeStar, Ashland, Ore). For kinetics assay, fresh isolated PBMCs were incubated in RPMI-1640 medium supplemented with 10% human AB serum (Sigma-Aldrich), 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L L-glutamine (all from Gibco, Life Technologies, Grand Island, NY). Recombinant human B-cell activating factor (BAFF) protein (R&D Systems, Minneapolis, Minn) was used at 10 ng/mL. A, Graphic representation of the U4atac RNA secondary structure on binding to U6atac (grey). Known MOPD1-implicated variants are shown in red, and previously described Roifman syndrome-causing variants (orange) are compound heterozygous for 1 variant in a MOPD1 region and a second in stem II or homozygous for a variant in the latter domain. Such compound heterozygous variants are also found for P1 and P2, whereas P3 is homozygous for a stem II variant (green). B, Pedigree of 3 patients with Roifman syndrome (P1-P3) from 2 kindreds (K1-K2) showing segregation of RNU4ATAC variants. C, Clinical images representing the retinal phenotype of P1 and P2 (i and ii, respectively). Optic discs are pale, white arrows show narrowed blood vessels, and the black arrow shows macular edema. Retinal dystrophy is less marked in P2 than in P1. Skeletal radiographs showing flattened biconvex vertebrae and mild osteopenia, flattening and broadening of proximal tibial epiphysis with flattened eminentia intercondylaris (P2, iii and iv), and bilateral dysplastic proximal epiphyses of the femora (P3, v). D, Sanger sequencing. Kindred 1: P1 and P2 inherited the c.G16A allele from the father and the c.G46A allele from the mother. Kindred 2: P3 is homozygous for the c.G16A variant, and both his parents are heterozygous.
Serologic assessment
Circulating levels of BAFF were measured by using human BAFF Quantikine ELISA (R&D Systems). A proliferation-inducing ligand (APRIL) was measured using human APRIL Quantikine ELISA (R&D Systems). Cytokine plasma concentrations were quantified by using an electrochemiluminescence immunoassay with V-Plex human proinflammatory panel Meso Scale Discovery plates. Samples and standards were prepared according to each manufacturer's instructions.
Natural killer cell assays
Natural killer (NK) cell assays were performed, as previously described. 20 Briefly, NK cytotoxicity was measured in a 51 Cr release assay. PBMCs were cultured with the NK-sensitive human K562 leukemia cell line (ATCC, Manassas, Va), which lacks expression of MHC class I. 51 Cr-labeled K562 cells were cultured for 4 hours with PBMCs (2.5-3 3 10 6 /mL) at a 50:1 effector/target cell ratio, and 51 Cr release was measured. Spontaneous and maximal release were determined by means of incubation of labeled target cells with medium or saponin (Merck, Whitehouse Station, NJ), respectively. Specific lysis was calculated as follows:
ðExperimental release2Spontaneous releaseÞ= ðMaximal release2Spontaneous releaseÞ3100:
The degranulation capacity of NK cells was measured by induction of CD107a surface expression after 2 hours of incubation of PBMCs (0.2 3 10 6 /mL) with K562 cells (1:1). Perforin and granzyme expression was analyzed ex vivo by using intracellular flow cytometry. For intracellular expression of IFN-g in NK cells determined by using flow cytometry, PBMCs were cultured for 6 hours in the presence of K562 cells (1:1), with addition of BD GolgiStop (1:150) and GolgiPlug (1:100; both from BD Biosciences, San Jose, Calif) for 5 hours.
Functional platelet studies
Platelet aggregation in response to different concentrations of multiple platelet agonists and ATP secretion were assessed by means of aggregometry, as previously described. 21 In addition, flow cytometry was performed on plateletrich plasma (PRP) obtained from citrated blood. After stimulating platelets with different agonists for 10 minutes at room temperature, CD62P-phycoerythrin was added to this suspension and incubated for 15 minutes in the dark before fixing (CellFix from BD Biosciences). Platelet number and size were also assessed on citrated whole blood by using CD41a to identify platelets. Finally, dense granule functionality was investigated through a mepacrine (Q3251; Sigma) uptake/release assay. 22 Diluted PRP was incubated with different concentrations of mepacrine for 30 minutes in the dark, followed by activation of half of the sample with 50 mmol/L thrombin receptor-activating peptide for 15 minutes and sample fixation. Data were acquired on a FACSCanto II HTS and analyzed with FACSDiva software (all from BD, Franklin Lakes, NJ).
Platelet electron microscopy
Peripheral blood was anticoagulated with trisodium citrate and centrifuged to obtain PRP. Samples were prepared, as previously described, 23 and analyzed blindly with a transmission electron microscope (EM 900; Zeiss, Heidelberg, Germany). Platelet morphology, size, and a-granules were further evaluated by using ImageJ software (National Institutes of Health, Bethesda, Md). Platelet shape and size were evaluated by using 37000 electron microscopic (EM) images. Platelets were manually identified, and platelet roundness was calculated as follows:
The mean value per EM image (containing 5-15 platelets) was used for further analysis. a-Granules were identified, measured, and counted manually based on 320,000 EM images. a-Granule numbers and mean a-granule size were quantified per platelet.
Human CD34
1 hematopoietic stem cell isolation and megakaryocyte differentiation Megakaryocte (MK) differentiation from peripheral blood-derived CD34 1 hematopoietic stem cells (HSCs) was performed, as described previously. 17, 24 In brief, HSCs were cultured in StemSpan SFEM medium with StemSpan CC100 ensuring strong expansion of undifferentiated HSCs for 3 days (STEMCELL Technologies, Vancouver, British Columbia, Canada). Differentiation was initiated by adding 50 ng/mL thrombopoietin, 25 ng/mL stem cell factor, and 10 ng/mL IL-1b (PeproTech, Rocky Hill, NJ). On day 6 of differentiation, 50 ng/mL thrombopoietin was resupplemented, resulting in proplatelet-forming MKs by days 11 to 12. MKs were counted manually based on cell-culture images, which were divided into quadrants. MKs were termed proplatelet forming if they started to extend at least 1 protrusion.
Immunostaining of MKs and platelets
Day 12 differentiated MKs were incubated on fibrinogen-coated coverslips for 3 to 4 hours at 378C. Citrated PRP was left for 30 minutes at room temperature and next diluted 1:50 in Tyrode buffer. Platelets were fixed for 10 minutes in a final concentration of 4% paraformaldehyde before being spun onto poly-L-lysine-coated coverslips for 10 minutes at 600 G. 25 Attached cells were treated, as previously described, 17, 21, 26 and incubated with antibodies (see the Methods section in this article's Online Repository). MKs were analyzed with a confocal microscope (AxioObserver.Z1; Zeiss), and platelet imaging was performed with a structured illumination microscope (Elyra S.1; Zeiss).
Images were analyzed with ZEN Black (Zeiss) and ImageJ software. For the confocal images, cell-surface area was determined based on F-actin staining. Granule counting was performed after applying the default threshold image through ''Analyze particles'' after a median filter was applied to and subtracted from the original. Three random control images were used to optimize parameters for each staining, which were then put into a macro for automated image analysis. MKs were included only in DNA ploidy analysis if the number of nuclei was clear from either F-actin or granule staining. On the other hand, the raw 3-dimensional SIM images were processed to SR-SIM by using the automatic algorithm of ZEN Black software, followed by maximumintensity projection. Resting platelets were selected on minimal size (>2 mm) and circularity (>0.7) for a-tubulin staining and manually selected for F-actin staining. Corrected total cell fluorescence was measured for both markers by using the following formula:
Integrated Density2ðArea of selected cell 3
Mean fluorescence of background readingsÞ:
Three regions around the platelet were taken into account to calculate mean background fluorescence. Granule counting for platelets was performed in analogy with the MK analysis.
Western blot analysis of platelets
Platelet lysates were prepared, as previously described. 17 Equal amounts of platelet lysates using 10 mg for a-granule and 20 mg for dense granule markers (and diaphanous related formin 1 [DIAPH1]) were evaluated by using antibodies (see the Methods section in this article's Online Repository). Immunoblots were analyzed with ChemiDoc XRS1 (Bio-Rad Molecular Imager; BioRad Laboratories, Hercules, Calif) and Image Lab 5.2.1 software (Bio-Rad Laboratories).
RNA sequencing and analysis
Starting material for RNA sequencing (RNAseq) was either ex vivo FACSsorted CD10 1 cells or day 11 MK cultures differentiated from HSCs. Details for RNAseq and data analysis are provided in the Methods section in this article's Online Repository. RT-PCR was performed on RNA of mature MKs of all 3 patients to confirm minor intron retention in DIAPH1 and Hermansky-Pudlak syndrome 1 (HPS1) with the primers 59GTTCACATCAGAAGTGAACT39 and 59CCGTTCTTGTGCAGAACTAT39 and 59AGCACCTGGCTGGAGTTTAA39 and 59CTTAGTTTTGACAAAGGCAG39, respectively. cDNA and intron retention analysis RNA was extracted with PAXgene Blood RNA tubes (PreAnalytix, Hombrechtikon, Switzerland), and cDNA was created with GoScript Reverse Transcription System (Promega, Madison, Wis), according to the manufacturer's recommendations. PCR to confirm intron retention in mitogen-activated protein kinase 1 (MAPK1) and XRCC5 was performed with the following intron spanning primers: 59TTCGAGCACCAACC ATCGAG39 and 59TCACAGGTGGTGTTGAGCAG39 and 59ATGGCACT GACAATCCCCTT39 and 59TGTTTCATGTTGAATCACATCCAT39, respectively.
Statistics
Statistical analysis was performed with Prism software (GraphPad Software, La Jolla, Calif). Healthy control subjects and patients with Roifman syndrome were systematically analyzed as 2 groups by using both-sided unpaired t tests for the B-cell experiments. Platelet and MK data were modeled and analyzed with several R packages (see Methods section in this article's Online Repository) after outlier removal using the robust regression and outlier removal method implemented in Prism software. 27 
Study approval
All subjects or their legal guardians provided informed consent before inclusion in the study. The study was approved by the Ethics Committee of UZLeuven (study nos. S52653 and ML3580). Patients were included in the multicenter National Institute for Health Research BioResource-Rare Disease study for patients with diverse rare inherited diseases, including bleeding and platelet disorders and primary immune deficiencies.
RESULTS
Clinical presentation of Roifman syndrome in 3 patients with rare variants in RNU4ATAC
We analyzed 3 patients who were given a clinical diagnosis of Roifman syndrome from 2 unrelated kindreds of Belgian European descent (Fig 1, B, and Table I ). P1 and P2 were both born prematurely (32 and 34 weeks of gestation) with low birth weights (22.6SD and 22.1SD) and had intrauterine growth retardation (see Fig E1 in this article' s Online Repository at www.jacionline.org). P3 was born at term with a birth weight of 2500 g (22.6SD) and length of 44 cm (23.6SD).
All patients have moderate psychomotor delay and autism spectrum disorder. They were all given a diagnosis of retinal dystrophy with hypovascularization (Fig 1, C) , and P3 experiences eye motility problems. All manifest severe growth retardation. Skeletal X-rays revealed spondyloepiphysial dysplasia with irregularly shaped vertebral bodies with platyspondyly and flattened proximal femoral epiphyses in all patients (Fig 1, C) . In addition, all patients manifest pruritic ichthyosis-like skin rash, brachydactyly, hyperlaxity, hypotonia, and hepatosplenomegaly. All patients have a clear endocrinologic phenotype. Delayed puberty was common to all, and P3 also exhibited hypogenitalism. Furthermore, P1 and P2 had minor increased circulating thyroid-stimulating hormone concentrations without clinical signs of hypothyroidism (Table I) , whereas P3 was given a diagnosis of and was treated for hypothyroidism in adulthood. Both P2 and P3 ultimately had hypergonadotropic hypogonadism (Table I) . Low levels of insulin-like growth factor were detected. Finally, all patients presented with absent adrenarche. Overall, P1 seems to display with a slightly more severe phenotype than his sister P2. P3 shows a milder phenotype than both siblings. DNA samples from the 3 patients underwent whole-genome sequencing as part of a research project coordinated by the National Institute for Health Research BioResource involving approximately 10,000 patients with rare diseases. The statistical association method for rare variants BeviMed 19 was applied to patients with Roifman syndrome (by using OrphaNet for labeling) and control subjects (ie, unrelated probands not labeled with Roifman syndrome). The top-ranking locus corresponded to RNU4ATAC, which had an estimated probability of association equal to 1.000 with Roifman phenotypes.
Cosegregation studies with Sanger sequencing confirmed the variants in the 3 patients and showed heterozygosity for the parents (Fig 1, B and D) . For the first kindred, siblings P1 and P2 were compound heterozygous for single nucleotide variants c.16G>A in the stem II region and c.46G>A in the critical region of RNU4ATAC (Fig 1, A and B) . Such a combination is in line with published data and supports the hypothesis that the presence of stem II variants determines the differential presentation of Roifman syndrome or MOPD1. 5 The single nucleotide variant c.16G>A was also present in one of the 5 previously described Roifman pedigrees, whereas c.46G>A was implicated in patients with MOPD1 with reduced severity. 5 P3 is homozygous for the stem II variant c.16G>A, making him the second patient with Roifman syndrome found to have this homozygous variant in the stem II region of RNU4ATAC. 
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High-depth immune phenotyping identifies a block at the transitional B-cell stage
Immunologic screening revealed that all patients have hypogammaglobulinemia and B-cell lymphopenia (Table I ). All patients experience recurrent viral infections, necessitating immunoglobulin substitution therapy. P2 had mucocutaneous Herpes simplex infection, and P3 presented a pneumococcal sepsis on discontinuation of therapy.
We further evaluated their immunologic profile by studying 53 different parameters using a flow cytometry platform. Results showed that although T-cell subset numbers and associated cytokine levels were within a normal range (see Table E1 in this article's Online Repository at www.jacionline.org), circulating (CD19 (Fig 2, A and B) . To determine the mechanism of transitional B-cell blockade, we performed RNAseq on CD10
1 B cells (see Worksheet E1 in this article's Online Repository at www.jacionline.org). Differential expression analysis identified splice factors and snRNA as the primary enrichment (see Table E2 and Fig E3 in this article' s Online Repository at www.jacionline.org), indicating compensatory upregulation after defective minor intron splicing. Of the 881 genes that contain a U12 intron, 28 178 expressed genes had minor intron retention within patients' transitional B cells (see Worksheet E2 in this article's Online Repository at www.jacionline.org). XRCC5 has a U12 intron (ID 28319), 28 and based on its function in repairing any DNA double-stranded breaks introduced during 
CD24
hi CD38 hi ). D and E, Percentage of rearrangements for V gene (Fig 2, D ) and J gene use (Fig 2, E) in purified CD10 1 cells. F, Median complementarity-determining region 3 length of IGH rearrangements. G, Pielou evenness index. *P < .05, **P < .005, and ****P < .00001.
V(D)J recombination, 29 defective XRCC5 splicing has been proposed as a cause of the B-cell deficiency seen in patients with Roifman syndrome. 5 Within transitional B cells, the U12 intron of XRCC5 was retained in P1, P2, and P3 (see Fig E4 in this article's Online Repository at www.jacionline.org). Therefore we assessed the BCR repertoire in both patients; however, there was no alteration in V(D)J recombination (Fig 2, D and E) . Furthermore, we evaluated the median complementarity-determining region 3 length of IGH rearrangements, which did not deviate from the healthy control subjects (Fig 2, F and G) . Together, the stage of B-cell differentiation blockade and the presence of normal BCR recombination demonstrate that the B-cell deficiency is not due to defective BCR rearrangement but rather is at a later stage of B-cell maturation.
BAFF signaling pathway is implicated in transitional B-cell blockade
Early B-cell differentiation is independent of BAFF, whereas mature B cells depend on BAFF and its interaction with B-cell activating factor receptor (BAFF-R). 30, 31 The transitional B-cell stage marks the point at which B cells become dependent on BAFF-R, with naive B cells binding BAFF exclusively through BAFF-R. 32, 33 BAFF-deficient mice manifest B-cell deficiency from the transitional stage onward, 30, 34 indicating the BAFF pathway as the only known biological pathway that would replicate the Roifman phenotype.
To assess whether BAFF expression was deficient in patients with Roifman syndrome, we measured plasma BAFF levels using ELISA in both healthy control subjects and patients. In line with previous work, 11 BAFF levels in patients with Roifman syndrome were significantly increased compared with those in healthy control subjects (Fig 3, A) . APRIL can also promote the proliferation and differentiation of B cells, and signaling through transmembrane activator and CAML interactor was not altered (Fig 3, B) . Therefore BAFF deficiency could be excluded, with the increase accounted for by decreased consumption because of B-cell lymphopenia (observed also in patients on B-cell depletion therapy, data not shown).
We next assessed BAFF-R expression in transitional B cells in both patients and control subjects. BAFF-R extracellular mean fluorescence intensity expression in transitional B cells (CD19
1
CD24
hi CD38 hi BAFF-R
1
) was lower than that in control subjects (Fig 3, C) . At an mRNA level, BAFF-R expression was unchanged (see Worksheet E1), and splicing was not altered. Because B-cell activating factor receptor (BAFF-R) can be internalized in the cell membrane, we performed intracellular staining; however, no major intracellular compartment was observed (data not shown). Therefore we tested the possibility that decreased BAFF-R expression was downstream of chronically increased BAFF levels. For the patients with Roifman syndrome, there was an inverse correlation found between BAFF and BAFF-R, with the lowest BAFF-R expression found on the B cells of patients with the highest concentration of circulating soluble BAFF (Fig 3, D) .
PBMCs from healthy control subjects (n 5 3) and patients (n 5 3) were cultured in BAFF-free media (CRPMI) and in media containing recombinant BAFF protein. We observed that patients' PBMCs cultured in CRPMI start to recover BAFF-R extracellular expression and, conversely, that healthy control B cells incubated with recombinant BAFF protein start to downregulate BAFF-R expression to levels observed in patients (Fig 3, E) . These results indicate that the reduction in BAFF-R levels in patients' B cells is secondary to the chronic increase in BAFF levels and does not drive the defect in transitional B cells.
Ingenuity pathway analysis of the 178 expressed genes with minor intron retention (see Worksheet E2) identified MAPK1 within defined major B-cell signaling pathways. A crucial mechanism through which BAFF promotes B-cell survival is downregulation of BIM, which is achieved by sustained activation of MAPK1. MAPK1 signaling phosphorylates BIM, promoting the ubiquitination and degradation of this proapoptotic factor. 33, 35 Thus BAFF-dependent survival of transitional B cells relies on MAPK1 signaling. In patients with Roifman syndrome, we observed a defect in removal of the minor intron (intron 2) in MAPK1 (Fig 3, F and G) . Intron retention introduces a stop codon in the reading frame that can account for the protein being truncated (Fig 3, H) . MAPK1 mRNA expression was moderately reduced in patients with Roifman syndrome (Fig 3, I) ; however, only 47% and 48% of the mRNA transcripts copies, P1 and P2, respectively, were spliced correctly (Fig 3, J) . Surviving B cells demonstrated a compensatory upregulation in MAPK1 protein expression; however, the concordant upregulation of the obligate MAPK3 heterodimer partner resulted in a skewed MAPK1/MAPK3 ratio (Fig 3, K) , potentially driving the observed disturbance in the cellular phenotype. This defect in the MAPK1-MAPK3 complex and the altered BAFF-BAFF-R relationship provides a potential mechanistic explanation for failure of B-cell differentiation at the transitional stage because the antiapoptotic pathway of BAFF-R would be specifically impaired, resulting in a failure of survival and further maturation into the naive B-cell state.
NK cell defects in patients with Roifman syndrome
As an independent immunologic disturbance, numbers of NK cells were also reduced in patients with Roifman syndrome (see Fig E5, A, in this article's Online Repository at www.jacionline. org), with a skewing toward the CD5 bright population (see Fig E5, B and C) . We further evaluated their cytotoxic functions based on 51 Cr release and a CD107a degranulation assay against the K562 tumor cell line. We observed that the percentage of 51 Cr release is reduced in all patients when compared with control subjects (see Fig E5, D) . The same tendency was not observed in the CD107a surface cell expression (see Fig E5, E and F) , indicating a specific defect in cytotoxicity rather than degranulation. Analysis of the expression of perforin and granzymes in NK cells indicated that levels of granzyme A, granzyme B, and perforin were decreased in the patients, whereas granzyme K levels were comparable with those in control subjects (see Fig E5, G-J) . Defective NK function can act as an independent factor contributing to some aspects of the immunodeficiency identified in patients with Roifman syndrome.
Platelet number, size, and function in patients with Roifman syndrome
Patients with Roifman syndrome presented with a decrease in platelet counts during clinical follow-up and remained mildly thrombocytopenic on reaching adolescence (Table I and see Fig  E6 in this article's Online Repository at www.jacionline.org). Such an age-related decrease in platelet counts is not typical for J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 2 patients with ITP, which is also defined as having a platelet count of less than 100 3 10 9 /L. 36 The mean platelet volume (MPV) was within normal limits, except for patient P1, who had mostly undetectable MPV values (Table I) .
Flow cytometry was performed on whole blood from P1 and an age-and sex-matched healthy control subject. No difference in platelet size could be detected between the patient and control subject, but P1 had reduced platelet numbers (see Fig E7 in this article's Online Repository at www.jacionline.org). Platelet ATP secretion and aggregation responses to different concentrations of collagen, ADP, and epinephrine were only reduced when platelet counts in PRP were less than 250 3 10 9 /L, which is typically used for functional testing (see Table E3 in this article's Online Repository at www.jacionline. org). To avoid this effect of platelet count on functional testing, flow cytometry detecting P-selectin (CD62P) release from a-granules after platelet activation was performed for P1 (see Table E3 ). Relative to an age-and sex-matched control subject, P1 responded normally to the agonists and even had slightly increased CD62P expression (see Fig E8 in this article's Online Repository at www.jacionline.org). Dense granule uptake and release using the mepacrine assay was normal for platelets of patient P1 (see Table E3 ). Despite the fact that platelets of all 3 patients with Roifman syndrome are reduced in number, platelet functions are normal, and the patients never presented with any obvious or trauma-related bleeding.
Altered platelet morphology and granulation in patients with Roifman syndrome
Platelet morphology was studied by using EM for P2 and P3, and platelet shape, size, and granules were compared with those of age-and sex-matched control subjects. EM revealed that platelets of patients with Roifman syndrome were more round instead of discoid (Fig 4, A and B) . Because of this roundness, platelets of patients with Roifman syndrome also appeared to be larger when evaluating EM slices (Fig 4, A and C) . However, both MPV values and flow cytometric data have demonstrated that platelet volume is normal. The presence of several enlarged a-granules was noticed (Fig 4, D) , and quantification revealed a slightly higher average a-granule size in patients with Roifman syndrome, although this was not significant. Numbers of a-granules were also normal (Fig 4, E) . In addition, a blinded pathologist described numerous dense granules in the platelets of patients with Roifman syndrome P2 and P3. Immunostaining for dense granule and lysosome marker CD63 on platelets of P3 also pointed to a significantly higher number of these organelles in comparison with a healthy control subject (Fig 4, F and G) . Western blot analysis of total platelet lysates showed increased levels of platelet a-granule-stored proteins von Willebrand factor (vWF) and thrombospondin 1, relative to platelet receptor integrin b3 (Fig 4, H, and see Fig E9, A, in this article's Online Repository at www.jacionline.org). In contrast to the normal dense granule mepacrine uptake and release and normal ATP secretion after platelet activation, platelets from patients with Roifman syndrome express increased levels of CD63 and lysosome-associated membrane protein 2, as detected by using Western blotting (Fig 4, H, and see Fig E9, B) . This would mean that platelets from patients with Roifman syndrome have increased numbers of dense granules with normal function. Additionally, a few rounder platelets of patients with Roifman syndrome showed granule centralization, and empty vacuoles were detected by using EM (see Fig E10 in this article' s Online Repository at www.jacionline.org).
Defective megakaryopoiesis for patients with Roifman syndrome
Because patients with Roifman syndrome have a reduced number of platelets with morphologic defects, in vitro megakaryopoiesis was studied by using peripheral blood-derived CD34 1 HSCs from the 3 patients and age-and sex-matched healthy control subjects. MKs at day 12 of differentiation contained more immature small MK cells for all patients with Roifman syndrome and a mild but significant reduction in proplatelet formation (Fig 5, A and D) . MKs from patients P1 and P2 were used for RNAseq, and MKs from patients P1 and P3 were used for detailed morphologic studies. Similar to healthy control subjects, MKs of patients with Roifman syndrome underwent endomitosis, which resulted in a very large and lobulated nucleus. The maturing MKs were evaluated by grouping cells on similar DNA ploidy levels to follow-up granule formation and cytoplasmic enlargement during this process. Immunostaining with the a-granule marker vWF (Fig 5, B) showed a significantly lower increase in a-granule numbers during MK maturation for patients with Roifman syndrome compared with healthy control subjects (Fig 5, E) . In contrast, only a mild but not significant decrease in dense granule numbers (using CD63 as a marker) was observed in the maturing MKs from patients with Roifman syndrome (Fig 5, B and F) . Moreover, F-actin immunostaining revealed that the cytoplasmic fraction of the patients' MKs remained smaller during this A, Circulating plasma BAFF concentration in patients and control subjects. B, Circulating APRIL concentration in plasma between patients and control subjects. C, BAFF-R mean fluorescence intensity (MFI) of transitional B cells (CD19 1 CD24 hi CD38 hi ). For healthy control subjects, boxes and whiskers represent ranges of 25% to 75% and 5% to 95% (n 5 29 or n 5 9, respectively). For patients, SEMs are shown. D, Correlation of circulating BAFF and BAFF-R MFI expression in healthy control subjects (n 5 9) and patients with Roifman syndrome (n 5 3). E, BAFF-R MFI on PBMCs of healthy control subjects (mean, n 5 3) and patients with Roifman syndrome after a short incubation period (15 and 60 minutes) with BAFF-free media (CRPMI) or media containing recombinant BAFF. A-C, Representative EM of platelets at 37000 magnification. Platelet size and roundness were calculated in 4 healthy control subjects versus P2 and P3. Scale bar 5 1.50 mm. D and E, EM images at 320,000 magnification were used for evaluation of a-granule size and number per platelet in the same subjects. Arrows indicate representative examples of a-granules. Scale bar 5 0.50 mm. Linear mixed-effects models were fitted to the logit of platelet roundness, the log of platelet size, and the log of mean a-granule size with sex and genotype as fixed effects and subjects as random effects. Analogously, a negative binomial mixed effects model was fitted for platelet a-granule numbers. F and G, Immunostaining of poly-L-lysine-immobilized platelets for CD63 and F-actin. Dense granule numbers were assessed per resting platelet for 1 healthy control subject versus P3. Scale bar 5 5 mm. A negative binomial regression model was fitted for dense granule number modeling genotype as a fixed effect. H, Western blot analysis on platelet lysate showing residual protein levels (accounting for the technical repeats) of a-granule markers vWF and thrombospondin 1 (TSP1) and dense granule (and lysosome) markers CD63 and lysosome-associated membrane protein 2 (LAMP2; 3 repeats of 2 healthy control subjects vs P1, P2, and P3). The log of the normalized intensity of each granule marker was modeled by using linear regression accounting for genotype and experiment. In all graphs boxes and whiskers represent ranges of 25% to 75% and 5% to 95%. HC, Healthy control subject.
process (Fig 5, C and G) . Because MKs of patients with Roifman syndrome appeared immature and were reduced in size, it was expected that granule formation would also be impaired. The strong decrease in a-granule numbers together with the small MK cell size results in a normal total a-granule number in platelets. On the other hand, dense granule numbers are only slightly lower in the MKs of patients with Roifman syndrome, generating platelets with slightly increased numbers of dense granules.
RNAseq of MKs from patients with Roifman syndrome showed aberrant minor intron retention
RNAseq was performed on differentiated MKs from patients P1 and P2 and 2 age-and sex-matched control subjects in duplicate cultures for each. MKs from patients with Roifman syndrome clearly clustered apart from control subjects on the basis of gene expression profiles (see Fig E11 in this article' s Online Repository at www.jacionline.org). Differential exon/intron use analysis identified 1390 alternatively used exon/intron bins between the 2 groups (with a false discovery rate < 0.05 and estimated fold change > 1.5; see Worksheet E3 in this article's Online Repository at www.jacionline.org). Of the 300 most significantly differing bins, 76% were an exact match to or overlapped with minor intron regions, confirming MKs are among the affected cell types in patients with Roifman syndrome. Thus aberrant minor intron splicing was found for 354 different genes, with organelle organization as the most enriched associated gene ontology term (see Table E4 in this article's Online Repository at www.jacionline.org). Interestingly, we detected highly significant intron retention in DIAPH1 (P 5 1.49 3 10 2127 ), HPS1 (P 5 5.95 3 10
256
), and RASGRP2 (P 5 9.43 3 10 2173 ), 3 genes known to be involved in platelet disorders (see Worksheet E3). 26, 37, 38 Confirmation studies were performed for the platelet and granule formation genes DIAPH1 and HPS1, respectively. Sashimi plots show the location and extent of intron retention in patients' MK samples (Fig 6, A) . RT-PCR analyses covering these regions confirmed that the minor introns are retained in MKs from P1, P2, and P3, whereas these alterations are not present in healthy control subjects (Fig 6, B) . Most interestingly, DIAPH1 is a cytoskeleton regulator that stimulates actin assembly and stabilizes microtubules. 39 Only recently, Stritt et al 26 showed the importance of these processes for platelet formation, as well as platelet cytoskeletal organization. They demonstrated that even small changes in DIAPH1 activity can cause macrothrombocytopenia by investigating platelets of patients with a dominant gain-of-function variant. Therefore we performed additional experiments to study the platelet cytoskeleton in P1 and P3.
Immunostaining for a-tubulin showed a normal distribution of microtubules but an increase in microtubule levels (Fig 7, A) . Moreover, F-actin levels were increased in platelets of patients with Roifman syndrome, which implies upregulation of actin polymerization (Fig 7, B) . Because our findings in patients with Roifman syndrome were milder but reminiscent of those in patients with DIAPH1 gain-of-function mutations, 26 we also evaluated protein expression. Western blot analysis of platelet lysate reveals a strong increase in DIAPH1 protein levels in patients with Roifman syndrome (Fig 7, C) . A feedback loop in response to incorrectly spliced RNA could explain this overcompensation, as previously suggested to be the case for 30% of the affected genes in patients with this disorder, 5 although this requires further confirmation studies.
DISCUSSION
Here we provide novel insight into the immune deficiency and thrombocytopenia reported in patients with Roifman syndrome using deep phenotyping and RNAseq of B cells and MKs of 3 patients from 2 unrelated kindreds who have causal variants in RNU4ATAC. In line with published data, 5, 11 patients P1 and P2 have one variant in the stem II region, which base pairs with another noncoding RNA for proper minor spliceosome loading, whereas the second variant is located in the RNU4ATAC critical regions implicated in the severe syndrome MOPD1. 12, 13 Previously, siblings who both have Roifman syndrome have been reported in whom the sister showed an overall milder phenotype than the brother, indicating skewed X-inactivation and possible discrepancy in intron retention could be present. 2, 11 In our study, although we observed this trend, albeit to a minor level, in the clinical phenotypes, systematic differences were not observed at the molecular level. Additionally, our study expands the known genetic space of mutations in patients with Roifman syndrome by describing a homozygous patient (P3) with a RNU4ATAC stem II variant, confirming that the disease can occur without the presence of a variant in MOPD1-implicated regions of the RNU4ATAC gene. In 2015, it was already postulated that the differential presentation of MOPD1 and Roifman syndrome was a consequence of the presence of a stem II variant 5 because no patients with MOPD1 have ever been reported with a variant is this domain. Now we can elaborate on this by verifying that RNU4ATAC variants in the stem II region are sufficient to cause the full spectrum of Roifman syndrome without the presence of mutations in the MOPD1 critical region. 11 Although all features of this disorder are present, P3 does present with a milder phenotype when compared with compound heterozygous patients with Roifman syndrome (P1 and P2) and is closer to the control population in several cellular assays performed. These findings can be explained potentially by the location of the variant, where the region can withstand several mutations and retain function as long as pairing with U6atac snRNA is preserved. 40 Therefore we could speculate that the disturbance of RNU4ATAC function caused by variants in MOPD1-implicated regions worsens the phenotype of Roifman syndrome.
Moreover, the distinct presentation of both disorders could be a consequence of variation in the subset of strongly affected genes and of severity of intron retention. However, further splicing studies on both patients with MOPD1 and those with Roifman syndrome would be needed to fully characterize the downstream effects of variants in the different regions of the RNU4ATAC gene.
The most striking immunophenotypic finding in patients with Roifman syndrome is the paucity of naive B cells accompanied by hypogammaglobulinema and clinical susceptibility to infection. This defect led to speculation by Merico et al 5 that intron retention in the XRCC5 gene leads to defective generation of the BCR repertoire, a process that would cause blockade of B-cell differentiation at the pre-/pro-B cell stages in the bone marrow. Here we formally exclude this possibility through 2 independent lines of evidence: (1) the normal appearance of transitional B cells, which was not observed in mice or patients with defects in BCR recombination, and (2) direct measurement of a normal BCR repertoire in patients. Instead, our cellular and molecular Scale bar 5 20 mm. C, Different stages in MK maturation are depicted by using immunostaining of CD63 and F-actin to demonstrate cytoskeletal changes. Scale bar 5 20 mm. D, Proplatelet formation was evaluated based on cell-culture images (3 healthy control subjects vs P1, P2, and P3). A linear mixed-effects model was fitted to the proportion of proplatelet-forming MKs with the experiment and genotype as fixed effects and the subjects as random effects. E and F, The rate of a-granule (Fig 5, E) and dense granule (Fig 5, F) formation was evaluated in maturing MKs by dividing them into ploidy groups. Differences in slope were investigated based on 2 differentiations of a healthy control subject versus P3 and 1 differentiation of 2 healthy control subjects versus P1. G, Cytoplasmic enlargement was evaluated in these MKs by using F-actin staining. In all graphs boxes and whiskers represent ranges of 25% to 75% and 5% to 95%. Negative binomial mixed-effects models were fitted for MK a-granule and dense granule numbers, accounting for the fixed-effects ploidy, genotype, and their interaction and modeling the fluctuations among subjects as random effects. An analogous linear mixed-effects model was fitted to the log of MK cell size. The interaction term will capture the ploidy-dependent slope, being the rate of the increase in granule number and cell size. HC, Healthy control subject. The transitional B-cell stage marks the point at which B cells become dependent on BAFF-R for survival, 35, 41 with MAPK1 signaling required to counter the proapoptotic function of BIM in transitional and naive B cells. 41 Defects in BAFF in mice phenocopy the B-cell differentiation pattern observed in patients with Roifman syndrome, 31, 41 providing a potential mechanistic basis for the cellular phenotype. BAFF was highly abundant in patients with Roifman syndrome, thus reducing BAFF-R expression because of the B-cell immunodeficiency. 42 An independent molecular analysis identified MAPK1 splicing as a major impairment in patients with Roifman syndrome, with fewer than half of the mRNA transcripts showing correct splicing over the exon 2 to 3 minor intron boundary. Despite compensatory mechanisms reducing the disparity at the protein level, this defect led to distorted ratios of the constituent components of the MAPK1-MAPK3 heterodimer signaling complex. With MAPK1-MAPK3 heterodimers being required for the prosurvival function of BAFF signaling, this defect provides a sufficient explanation for the observed phenotype, although it does not exclude the presence of other B cell-intrinsic defects in differentiation and survival caused by loss of the minor splicing complex.
Notably, defects at this later stage of B-cell differentiation might provide a unique therapeutic target for the immunodeficiency component of Roifman syndrome. Although BCR recombination defects can only be treated through bone marrow transplantation, a problematic solution for syndromic patients, the molecular analysis presented here suggests that peripheral agonism of MAPK1 or antagonism of BIM would be sufficient to rescue the survival of transitional B cells and allow the differentiation of a fully functional naive B-cell pool.
The 3 reported patients also show a slightly reduced number of platelets with normal function. Previously, it was proposed that thrombocytopenia in patients with Roifman syndrome is immune mediated, as in patients with ITP. In 2003, Roifman and Melamed 16 reported on one case that responded well to intravenous immunoglobulin treatment. However, another patient with Roifman syndrome responded poorly to intravenous immunoglobulin. Our findings revealed MK and platelet defects in patients with Roifman syndrome, elucidating that the observed mild thrombocytopenia is inherent to the disorder and not just secondary to the immunologic defects. Moreover, 354 genes in MKs from patients with Roifman syndrome undergo aberrant splicing, and it is expected that such defects modify megakaryopoiesis, especially because most inherited thrombocytopenias are dominant as result of only a single gene variant. 43 EM analysis, immunostaining, and Western blotting showed rounder platelets that contain slightly more dense granules and some enlarged a-granules. Markers of a-granules and dense granules were strongly increased. Such defects are not typical for ITP, which results from increased removal of antibody-coated platelet by the spleen. (Fig 7, A) and F-actin (Fig 7, B) . Corrected total cell fluorescence (CTCF) values were compared for 2 healthy control subjects versus P1 and P3. In both graphs boxes and whiskers represent ranges of 25% to 75% and 5% to 95%. Linear mixed-effects models were fitted to CTCF values of both cytoskeletal components accounting for the genotype as fixed effect and the different subjects as random effects. C, DIAPH1 protein levels were evaluated by means of Western blotting in parallel with platelet marker integrin b3 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 2 healthy control subjects vs P1, P2, and P3). HC, Healthy control subject.
We found that HSCs of patients with Roifman syndrome undergo abnormal megakaryopoiesis with reduced proplatelet formation, have smaller MKs because of aberrant cytosol maturation, and, as a consequence, have decreased a-granule formation during MK maturation. This would implicate that the snRNA U4atac regulates splicing of genes during megakaryopoiesis. The importance of RNA processing and small RNAs for megakaryopoiesis can be expected based on a number of studies, [44] [45] [46] [47] [48] but its role in pathology is unknown. The only other syndrome that points to the importance of correct RNA processing in megakaryopoiesis is thrombocytopenia with absent radius syndrome. 49 Compound heterozygous variants are present in RBM8A, which encodes a subunit of the exon-junction complex involved in nuclear export and localization of specific transcripts, translation, and nonsensemediated RNA decay. However, it is still unknown how defects in this pathway affect megakaryopoiesis in patients with thrombocytopenia with absent radius syndrome.
We hypothesize that defects in minor splicing affect multiple genes important for MK and platelet function and that they each could contribute to the overall phenotype. Significant minor intron retention was detected in 354 genes, among which 2 genes previously associated with platelet phenotypes comparable with those observed in patients with Roifman syndrome (ie, DIAPH1 26 and HPS1 37 ). The technical and biological replicate RT-PCR confirmed intron retention for both DIAPH1 and HPS1 transcripts. Interestingly, a dominant gain-of-function variant in DIAPH1 was reported recently to cause macrothrombocytopenia with normal platelet function though abnormal morphology. 26 These patients have reduced proplatelet formation in MK assays, and EM of their platelets showed enlarged platelets with some giant a-granules. Aberrant tubulin and actin levels were also noticed in platelet immunostaining, all of which were remarkably similar to those found for patients with Roifman syndrome. The dominant p.R1213* DIAPH1 variant resulted in a premature stop located in the diaphanous autoregulatory domain, which interacts with the diaphanous inhibitory domain to limit DIAPH1 activity. The observed intron 11 to 12 retention would result in a premature stop leading to mRNA decay or a truncated shorter protein in the middle of the dimerization domain (see Fig E12, A, in this article's Online Repository at www.jacionline.org). Western blot analysis did not reveal the presence of a smaller truncated protein but rather enhanced DIAPH1 expression.
Therefore we hypothesize that the presence of incorrectly spliced mRNA leads to a strong increase in DIAPH1 transcription through a feedback loop. Such an overcompensation mechanism was previously suggested for other genes studied in patients with Roifman syndrome. 5 Recessive variants in HPS1 are known to cause Hermansky-Pudlak syndrome, 50, 51 in which multiple patients' platelets showed dense granule defects, indicating its central role in formation of these platelet organelles. 50 HPS1 is a component of the biogenesis of lysosome-related organelles complex 3 (BLOC3) and is thought to play a role in coordinating the transport of cargo into developing granules. 51 Our patients with Roifman syndrome show the opposite dense granule phenotype because their platelets contain a slightly higher number of dense granules and have increased storage of dense granule protein. The minor intron retention observed in HPS1 in MKs from patients with Roifman syndrome is located in one of 2 HPS1 regions that interacts with HPS4 (see Fig E12, B) , another BLOC3 component. 52 Our findings indicate that minor intron retention might enhance or stabilize HPS1 and HPS4 interaction and therefore also promote BLOC3 function, although additional studies are required to support this.
In conclusion, we describe 2 patients with compound heterozygous variants and 1 with a homozygous variant located in stem II and presenting with a milder phenotype. We identified the transitional B cell as the key cell type affected by loss of minor intron splicing, with a blockade in further differentiation, despite the presence of a normal BCR repertoire. Defective MAPK1 minor intron splicing is sufficient to explain this defect, with the known biological role in coupling BAFF signaling to transitional B-cell survival. At the hematologic level, we identified defective MK differentiation as the most likely cause for the observed thrombocytopenia, with defective splicing of DIAPH1 and HPS1 potentially explaining the reduction in platelet formation and presence of abnormal granules. In all, our results provide new insights into the role of minor intron splicing in the hematopoietic and immune systems, mechanistically explain key phenotypic features, and identify valuable therapeutic intervention targets for clinical management of aspects of Roifman syndrome.
This study makes use of whole-genome sequencing data and analytic approaches generated by the National Institute for Health Research BioResource-Rare Disease BRIDGE Consortium. The structured illumination microscope was acquired through a CLME grant from Minister Lieten to the VIB BioImaging Core.
Key messages
d Defects in the minor splicing complex drive a drive a defect in B-cell differentiation, leading to humoral immunodeficiency in patients with Roifman syndrome.
d Our findings highlight a critical role for minor intron splicing by U4atac during megakaryopoiesis and granulopoiesis.
